• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » CSL Behring expands operations to Russia

CSL Behring expands operations to Russia

December 9, 2015
CenterWatch Staff

CSL Behring, a global biotherapeutics company, has announced its latest geographic expansion to provide more patients with greater access to treatment by opening operations in Russia.

The move is particularly significant in Russia, where the healthcare system has some unmet needs for state-of-the-art biotherapies and blood plasma products.

With operations in more than 30 countries, CSL Behring focuses on developing novel, protein-based therapies for the treatment of bleeding disorders, immune deficiencies, inherited respiratory disease and hereditary angioedema, and for neurological disorders in certain markets. CSL Behring is a subsidiary of CSL Limited.

CSL CEO and Managing Director Paul Perreault said the new office enables CSL Behring to partner more closely with the Russian Federation, healthcare providers, patient groups and the scientific community. He noted that CSL Behring will be closer to patients, will listen to them more carefully and will better understand their medical needs. The company currently has seven products registered in Russia.

“It is this process of listening and engaging that enhances our ability to deliver new and innovative medicines that make such a huge difference in people’s lives,” Perreault said. He added that it will now be easier to launch products in Russia and offer new therapy options to doctors and their patients.

In addition, CSL Behring is investigating opportunities to contribute to the development of the Russian pharmaceutical industry, and identify the best ways to partner with the Russian government. As an example, because the amount of human plasma currently collected in Russia is insufficient to meet the growing demand for protein-based medicines, Perreault said it may be possible to transfer CSL Behring’s plasma collection technology to Russia, and initiate toll manufacturing in that country.

Over the last five years, CSL has invested more than $2 billion in research and development, employing more than 1,100 R&D experts.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Revamp-360x240.png

    Califf Calls for Major Evidence Generation Revamp, Experts’ Opinions Differ

  • AskTheExpertsGreen-360x240.png

    Ask the Experts: Managing Investigational Products

  • SurveywBlueBackground-360x240.png

    Survey Outlines Site Challenges, Successes on Diversity

  • PatientCentricity-360x240.png

    Site Spotlight: DM Clinical Shows Patient Centricity Doesn’t Have to Break the Bank

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing